Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

VBL Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26th in New York

Posted on: 14 Sep 17

TEL AVIV, Israel, Sept. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT),  a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference.  The conference will be held September 25-27, 2017 at the InterContinental New York Barclay Hotel, New York City.

Presentation Details:

Date:  Tuesday, September 26, 2017

Time:  9:45-10:15 AM Eastern Time

Location:  Grand Ballroom 2; InterContinental New York Barclay Hotel

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).


CONTACT: INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979 MEDIA CONTACT: Matt Middleman, M.D. LifeSci Public Relations (646) 627-8384GlobeNewswire

Last updated on: 15/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.